US Patent

US9192608 — Morphine formulations

Method of Use · Assigned to Becton Dickinson France SA · Expires 2034-03-12 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical formulations, including injectable morphine formulations with improved stability, and methods for producing and using them.

USPTO Abstract

Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.

Drugs covered by this patent

chembl-chembl2103744 (MORPHINE SULFATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-43`	—	chembl-chembl2103744
`U-55`	—	chembl-chembl2103744
`U-43`	—	chembl-chembl2103744
`U-43`	—	chembl-chembl2103744
`U-55`	—	chembl-chembl2103744

Patent Metadata

Patent number: US9192608
Jurisdiction: US
Classification: Method of Use
Expires: 2034-03-12
Drug substance claim: No
Drug product claim: No
Assignee: Becton Dickinson France SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.